Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InflaRx (IFRX) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for InflaRx (IFRX) over the last 4 years, with Q3 2025 value amounting to $21.5 million.

  • InflaRx's Cash & Equivalents rose 5320.59% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 5320.59%. This contributed to the annual value of $13.8 million for FY2024, which is 59.47% up from last year.
  • As of Q3 2025, InflaRx's Cash & Equivalents stood at $21.5 million, which was up 5320.59% from $20.8 million recorded in Q2 2025.
  • InflaRx's Cash & Equivalents' 5-year high stood at $29.5 million during Q1 2022, with a 5-year trough of $13.6 million in Q4 2024.
  • Moreover, its 4-year median value for Cash & Equivalents was $17.7 million (2023), whereas its average is $19.6 million.
  • Per our database at Business Quant, InflaRx's Cash & Equivalents plummeted by 4870.51% in 2023 and then surged by 5320.59% in 2025.
  • Over the past 4 years, InflaRx's Cash & Equivalents (Quarter) stood at $26.8 million in 2022, then crashed by 48.71% to $13.7 million in 2023, then fell by 0.68% to $13.6 million in 2024, then skyrocketed by 57.45% to $21.5 million in 2025.
  • Its Cash & Equivalents was $21.5 million in Q3 2025, compared to $20.8 million in Q2 2025 and $19.3 million in Q1 2025.